Fewer patients diagnosed with testicular cancer were uninsured, and fewer were diagnosed with late-stage disease, following the Affordable Care Act’s Medicaid enrollment expansion.
Researchers have discovered that testicular cancer’s responsiveness to conventional chemotherapy is likely determined during prenatal development.
Researchers found that combining palonosetron, aprepitant, and dexamethasone represents an effective and well-tolerated treatment to prevent CINV in testicular cancer patients receiving cisplatin.
A post-hoc analysis found that brain metastases are more frequent in patients with advanced germ cell tumors who have received dose-dense chemotherapy compared with those administered the BEP regimen.
In a small phase II study of 12 men with nonseminoma germ cell tumors refractory to cisplatin, pembrolizumab did not demonstrate clinical activity.
Researchers analyzed a large population-based sample of men from Sweden and discovered an association between heavy cannabis use and testicular cancer incidence.
In this video, Dr. Fizazi argues for treatment intensification for poor-prognosis germ cell tumor patients who display unfavorable marker decline.
In this video, Dr. Bosl argues against treatment intensification for poor-prognosis germ cell tumor patients who display unfavorable marker decline.
A new study is suggesting that a high percentage of testicular cancer survivors may suffer from hypogonadism.
Event-free survival was not maintained in children and adolescents with intermediate-risk malignant germ cell tumors when cisplatin-based chemotherapy was reduced from four to three cycles and compressed from 5 to 3 days per cycles.